Herantis Pharma: Key messages from today’s R&D webinar

Press release

Herantis Pharma Plc, Press release, 23 October 2024 at 8:30 AM EEST

Herantis Pharma’s R&D webinar will take place today, October 23, 2024 (10:00-11:00 EEST/9:00-10:00 CEST): 

Link to the R&D webinar: https://herantis.videosync.fi/webinar-10-2024

Herantis Pharma Plc (“Herantis”) is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease.

Herantis’ key messages:

• HER-096 shows preclinical evidence of being neurorestorative not just slowing, but also reversing neuronal damage for symptomatic improvement.
• HER-096 is administered by a patient-friendly, subcutaneous injections.
• Subcutaneous single dose injections of HER-096 had overall good safety and tolerability profile in healthy subjects in the Phase 1a clinical trial.
• Biomarker research program ongoing, with the goal to identify treatment response/pharmacodynamic biomarkers.
• Significant milestones going forward:
  • Q4 2024: Phase 1b, part 1 readout
  • Q1 2025: Phase 1b, part 2 starting dosing of Parkinson’s patients with HER-096
  • 2H 2025: Phase 1b topline data.

The primary objective of the Phase 1b trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease.

• 2026: Start of Phase 2, clinical proof-of-concept trial of HER-096
• Strong external validation of Herantis’ HER-096 program:
• • European Investment bank (€15M investment commitment)
  • European Innovation Council (€2.5M in grant R&D program)
  • The Michael J. Fox foundation and Parkinson’s UK (€3.6M in funding of Phase 1b trial)
  • Peer-reviewed publications

R&D Webinar Information:

Please use the following link to register for this event: https://herantis.videosync.fi/webinar-10-2024

After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event.

The recording of the webcast will be available on  https://herantis.com/news-events/video presentations/ following the event.

About HER-096:

HER-096 is an engineered peptidomimetic molecule designed to mimic the activity of CDNF, a protein that promotes cell survival and functional recovery of neurons. HER-096 modulates the Unfolded Protein Response (UPR) pathway, the regulation of which is essential in restoring the cell protein balance (proteostasis) and preventing the processes leading to, e.g., cytotoxic protein aggregation and neuronal cell death in the brain. In addition, HER-096 alleviates inflammation in the affected brain area. Thanks to its multimodal mechanism of action, Herantis’ HER-096 has the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Ltd

Tel.: +358 9 25 380 225

E-mail: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.

Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com

Forward-looking statements

This release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of operations, the Company’s strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “should” or “will” or the negative of such terms or other comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company’s actual results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis’ strategy, risks and uncertainties associated with the development and/or approval of Herantis’ drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis’ potential market and industry, Herantis’ freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors’ patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. In addition, even if Herantis’ historical results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.